(Mary Ann Liebert, Inc./Genetic Engineering News) A new study assessed the safety, tolerability, and effectiveness of extended-release guanfacine in children 6-17 years of age who have chronic tic disorders including Tourette's disorder.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2uZl14S
No comments:
Post a Comment